The 2012 National Plan to Address Alzheimer's Disease set an ambitious goal: to both
prevent and effectively treat Alzheimer's disease by 2025. To reach this goal, tens of …

Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer
to complete, and are more expensive than trials in most other therapeutic areas. The …

Background Global leaders have set an ambitious goal of developing interventions to
effectively treat or prevent Alzheimer's disease by 2025. Case presentation Achieving this …

Background: Low participation in clinical trials is a major challenge to advancing clinical
Alzheimer's disease (AD) research and care. Factors influencing recruitment to AD trials are …

Alzheimer disease (AD) research faces challenges to successful enrollment, especially to
clinical trials and biomarker studies. Failure to recruit the planned number of participants in a …

Potential participant registries are tools to address the challenge of slow recruitment to
clinical research. In particular, registries may aid recruitment to secondary prevention clinical …

Among the key challenges in Alzheimer's disease drug development is the timely
completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient …

Alzheimer's disease (AD) drug development is costly, time-consuming, and inefficient. Trial
site functions, trial design, and patient recruitment for trials all require improvement. The …

Abstract The National Alzheimer's Project Act identifies the effective treatment and
prevention of Alzheimer's by 2025 as an urgent public health mission. This priority is …

In light of our limited understanding of what motivates older adults to participate in clinical
studies of Alzheimer's disease (AD), the current study examines incentives and barriers to …